Teriparatide (PTH 1-34) 10mg

Description

Disclaimer: This compound is provided strictly for laboratory and scientific research purposes only. It is not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use, including ingestion, injection, or any form of administration.

Chemical Properties of the Compound

Formulation note: The acetate salt form (CAS 99294-94-7, MW 4,177.83 g/mol) is also available from some suppliers. The values above reflect the free peptide entry for CAS 52232-67-4. Researchers should confirm the specific form of the material in use, as the two variants differ in molecular weight and may affect experimental design.

Overview

Teriparatide is a synthetic 34-amino-acid peptide. It corresponds to the N-terminal fragment of parathyroid hormone (PTH). It is a parathyroid hormone receptor 1 (PTH1R) agonist. It is supplied by BC9 as a research-grade lyophilized peptide in vials. It is available for:

• In vitro PTH1R receptor binding investigation
• Preclinical bone remodeling pathway research
• Osteoblast biology laboratory studies

A pharmaceutical formulation of teriparatide is FDA-approved for specific clinical indications. However, the research-grade teriparatide supplied here is a distinct laboratory preparation. It is a 10mg lyophilized peptide vial produced for preclinical and in vitro research use only. It is not a pharmaceutical product, not a clinical preparation, and is not supplied for any human application. It is not a dietary supplement.

Working Mechanism of Teriparatide (PTH 1-34)

In preclinical cell and tissue models, teriparatide has been examined as a PTH1R agonist. In isolated receptor preparations and cell culture systems, PTH1R binding by teriparatide has been observed to activate adenylate cyclase, increasing intracellular cAMP levels and activating downstream protein kinase A (PKA) signaling cascades under controlled laboratory conditions.

Additional experimental data have explored associations with osteoblast biology pathways. In rodent preclinical models and isolated osteoblast cell systems, intermittent PTH1R activation has been associated with modulation of osteoblast differentiation, proliferation, and apoptosis pathways. Research in this area has investigated how PTH1R signaling may shift the balance between bone-forming and bone-resorbing cellular activity in experimental model systems.

These interactions remain under investigation, with variability across experimental models.

Research Findings / Research Applications

Preclinical investigations have examined Teriparatide (PTH 1-34) in relation to:

• PTH1R receptor binding kinetics and structure-activity relationship studies
• Osteoblast differentiation and apoptosis pathway investigation in primary cell culture
• RANKL/OPG signaling axis research in preclinical bone remodeling model systems
• Comparative PTH fragment pharmacology studies against full-length PTH(1-84) analogs
• Bone formation and resorption marker modulation studies (in rodent preclinical models)
• cAMP second messenger signaling research in PTH1R-transfected cell line systems

Note: These findings are based on early-stage and preclinical research. Results are not consistent across all models, and data remains limited without validation in human clinical settings.

Risks & Handling Information

• The use of appropriate personal protective equipment (PPE) is essential in conducting experiments. Required PPE: nitrile gloves, lab coat, and eye protection at a minimum.
• Handling should occur within controlled laboratory environments designed for research activities.
• Do not inhale, ingest, or make direct skin contact with the compound.
• The toxicological profile is not fully established. Exposure risks remain uncertain due to limited long-term safety data.
• Improper storage conditions, including exposure to heat, light, or moisture, may result in compound degradation and compromised sample integrity.

FAQs

Why is Teriparatide (PTH 1-34) classified as a research compound?

This is because the research-grade vial preparation has not received FDA approval for human or veterinary use in this form.

What is the difference between research-grade and pharmaceutical teriparatide?

A pharmaceutical formulation of teriparatide is FDA-approved for specific clinical indications under medical supervision. The research-grade vial preparation is a distinct laboratory compound produced strictly for preclinical and in vitro research use. It is not a pharmaceutical product and is not cleared for any human application.

What factors affect Teriparatide (PTH 1-34) peptide degradation?

Degradation is dependent on environmental factors. These include temperature, light exposure, moisture, and repeated freeze-thaw cycles. Peptide integrity may also be affected by improper reconstitution conditions, too.

How should Teriparatide (PTH 1-34) be stored?

Store vials at −20°C in a dry, dark environment, protected from light, heat, and moisture. Avoid repeated freeze-thaw cycles.

References

Jilka, R. L. (2007). Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone, 40(6), 1434–1446. https://pubmed.ncbi.nlm.nih.gov/17517365/

Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999). Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. Journal of Clinical Investigation, 104(4), 439–446. https://pubmed.ncbi.nlm.nih.gov/10449436/

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer satisfaction stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.